{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:03:23Z","timestamp":1775891003791,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/ncomms6870","type":"journal-article","created":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T10:37:49Z","timestamp":1418899069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models"],"prefix":"10.1038","volume":"5","author":[{"given":"Grit S.","family":"Herter-Sprie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houari","family":"Korideck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla L.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan M.","family":"Herter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross I.","family":"Berbeco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra A.","family":"Akbay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond H.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mike Makrigiorgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alec C.","family":"Kimmelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwok-Kin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,18]]},"reference":[{"key":"BFncomms6870_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9\u201329 (2014).","journal-title":"CA Cancer J. Clin."},{"key":"BFncomms6870_CR2","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jama.2010.261","volume":"303","author":"R Timmerman","year":"2010","unstructured":"Timmerman, R. et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303, 1070\u20131076 (2010).","journal-title":"JAMA"},{"key":"BFncomms6870_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ijrobp.2008.11.042","volume":"75","author":"AJ Fakiris","year":"2009","unstructured":"Fakiris, A. J. et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int. J. Radiat. Oncol. Biol. Phys. 75, 677\u2013682 (2009).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFncomms6870_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nature10937","volume":"483","author":"Z Chen","year":"2012","unstructured":"Chen, Z. et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483, 613\u2013617 (2012).","journal-title":"Nature"},{"key":"BFncomms6870_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1667\/RR2157.1","volume":"174","author":"D Saha","year":"2010","unstructured":"Saha, D. et al. An orthotopic lung tumor model for image-guided microirradiation in rats. Radiat. Res. 174, 62\u201371 (2010).","journal-title":"Radiat. Res."},{"key":"BFncomms6870_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1667\/RR2565.1","volume":"176","author":"B Li","year":"2011","unstructured":"Li, B. et al. A novel bioluminescence orthotopic mouse model for advanced lung cancer. Radiat. Res. 176, 486\u2013493 (2011).","journal-title":"Radiat. Res."},{"key":"BFncomms6870_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ng1490","volume":"37","author":"A Sweet-Cordero","year":"2005","unstructured":"Sweet-Cordero, A. et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 37, 48\u201355 (2005).","journal-title":"Nat. Genet."},{"key":"BFncomms6870_CR8","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.ijrobp.2009.11.038","volume":"76","author":"DG Kirsch","year":"2010","unstructured":"Kirsch, D. G. et al. Imaging primary lung cancers in mice to study radiation biology. Int. J. Radiat. Oncol. Biol. Phys. 76, 973\u2013977 (2010).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFncomms6870_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fonc.2013.00072","volume":"3","author":"BA Perez","year":"2013","unstructured":"Perez, B. A. et al. Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice. Front. Oncol. 3, 72 (2013).","journal-title":"Front. Oncol."},{"key":"BFncomms6870_CR10","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1101\/gad.943001","volume":"15","author":"EL Jackson","year":"2001","unstructured":"Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243\u20133248 (2001).","journal-title":"Genes Dev."},{"key":"BFncomms6870_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nature06030","volume":"448","author":"H Ji","year":"2007","unstructured":"Ji, H. et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807\u2013810 (2007).","journal-title":"Nature"},{"key":"BFncomms6870_CR12","doi-asserted-by":"publisher","first-page":"10280","DOI":"10.1158\/0008-5472.CAN-05-2193","volume":"65","author":"EL Jackson","year":"2005","unstructured":"Jackson, E. L. et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280\u201310288 (2005).","journal-title":"Cancer Res."},{"key":"BFncomms6870_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0360-3016(02)02989-9","volume":"54","author":"A Bezjak","year":"2002","unstructured":"Bezjak, A. et al. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int. J. Radiat. Oncol. Biol. Phys. 54, 719\u2013728 (2002).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFncomms6870_CR14","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.ijrobp.2003.08.005","volume":"58","author":"CK Cross","year":"2004","unstructured":"Cross, C. K., Berman, S., Buswell, L., Johnson, B. & Baldini, E. H. Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 1098\u20131105 (2004).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFncomms6870_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-2600(13)70009-2","volume":"1","author":"GM Stella","year":"2013","unstructured":"Stella, G. M., Luisetti, M., Pozzi, E. & Comoglio, P. M. Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Resp. Med. 1, 251\u2013261 (2013).","journal-title":"Lancet Resp. Med."},{"key":"BFncomms6870_CR16","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/nprot.2009.95","volume":"4","author":"M DuPage","year":"2009","unstructured":"DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064\u20131072 (2009).","journal-title":"Nat. Protoc."},{"key":"BFncomms6870_CR17","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379\u20135388 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFncomms6870_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.CIR-13-0115","volume":"1","author":"EB Golden","year":"2013","unstructured":"Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A. & Formenti, S. C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1, 365\u2013372 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"BFncomms6870_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1139\/o03-042","volume":"81","author":"DR Pilch","year":"2003","unstructured":"Pilch, D. R. et al. Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem. Cell Biol. 81, 123\u2013129 (2003).","journal-title":"Biochem. Cell Biol."},{"key":"BFncomms6870_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature07423","volume":"455","author":"L Ding","year":"2008","unstructured":"Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069\u20131075 (2008).","journal-title":"Nature"},{"key":"BFncomms6870_CR21","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1126\/science.1082504","volume":"300","author":"M Garcia-Barros","year":"2003","unstructured":"Garcia-Barros, M. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155\u20131159 (2003).","journal-title":"Science"},{"key":"BFncomms6870_CR22","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071\u20131078 (2009).","journal-title":"Nature"},{"key":"BFncomms6870_CR23","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrc3342","volume":"12","author":"P Bouwman","year":"2012","unstructured":"Bouwman, P. & Jonkers, J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer 12, 587\u2013598 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"BFncomms6870_CR24","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1371\/journal.pone.0000810","volume":"2","author":"L Regales","year":"2007","unstructured":"Regales, L. et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2, e810 (2007).","journal-title":"PLoS One"},{"key":"BFncomms6870_CR25","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1118\/1.1374247","volume":"28","author":"CM Ma","year":"2001","unstructured":"Ma, C. M. et al. AAPM protocol for 40-300 kV x-ray beam dosimetry in radiotherapy and radiobiology. Med. Phys. 28, 868\u2013893 (2001).","journal-title":"Med. Phys."}],"updated-by":[{"DOI":"10.1038\/s41467-020-15348-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms6870.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms6870","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms6870.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T02:22:06Z","timestamp":1672971726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms6870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,18]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,23]]}},"alternative-id":["BFncomms6870"],"URL":"https:\/\/doi.org\/10.1038\/ncomms6870","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,18]]},"assertion":[{"value":"11 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.H.M. served as a consultant to Boehringer Ingelheim. A.C.K. serves as a consultant to Forma Therapeutics. K.-K.W. owns equity in and receives compensation from G1 Therapeutics, serves as a consultant to MolecularMD and has sponsored research agreements with AstraZeneca, Gilead, Takeda and Millennium Pharmaceuticals. The remaining authors declare no competing financial interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5870"}}